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Abstract  
Background:  The International Agency for Research on Cancer (IARC) has determined there is 
sufficient evidence that working in the rubber manufacturing industry increases the risk of cancers of 
the stomach, lung, bladder, and leukaemia and lymphoma. 
Objectives:  To examine mortality patterns of a prospective cohort of men from the rubber and cable 
manufacturing industries in Great Britain. 
Methods:  Standardised Mortality Ratios (SMRs) were calculated for males aged 35+ at start of follow-
up in 1967 to 2015 using the population of England and Wales as the external comparator. Tests for 
homogeneity and trends in SMRs were also completed. 
Results:  For all causes, all malignant neoplasms (MNs), non-malignant respiratory diseases (NMRDs), 
and circulatory diseases (CDs), SMRs were significantly elevated, and also particularly for cancers of 
the stomach (SMR = 1.26 [95% Confidence Interval [CI] 1.18 to 1.36]), lung (1.25 [95% CI 1.21 to 
1.29]), and bladder (1.16 [95% CI 1.05 to 1.28]). However, the observed deaths for leukaemia, non-
Hodgkin’s lymphoma (NHL), and multiple myeloma were as expected. Bladder cancer risks were 
elevated only in workers exposed to antioxidants containing 1- and 2-naphthylamine. 
Conclusions:  This study provides evidence of excess risks in the rubber industry for some non-cancer 
diseases and supports IARC’s conclusions in relation to risks for cancers of the bladder, lung, and 
stomach, but not for leukaemia, NHL, or multiple myeloma. 
Key Words: rubber and cable industry; industrial cohort study; mortality; cancer; circulatory and 
respiratory diseases 
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Key Messages: 
1. According to the International Agency for Research on Cancer (IARC), 
working in the rubber industry increases the risk of cancer of the urinary 
bladder, lung, stomach and of leukaemia, non-Hodgkin’s lymphoma (NHL) 
and multiple myeloma. 
2. This paper confirms earlier findings from this study that removal of 
antioxidants containing 1-naphthylamine and 2-naphthylamine has 
reduced the bladder cancer risk in the cohort.  It confirms IARC’s views of 
an increased risk for cancers of the urinary bladder, lung and stomach, 
but does not  provide support for increased risks of leukaemia, NHL or 
multiple myeloma and provides evidence that work in the rubber industry 
is associated with an increased risk in circulatory diseases (ischaemic 
heart diseases and cerebrovascular disease) and non-malignant 
respiratory diseases (bronchitis). 
3. Occupational physicians and health and safety managers within the 
industry should remain aware of the associated hazardous exposures and 
ensure they are kept to a level that is as low as reasonably practical. 
4 
 
Introduction 
The International Agency for Research on Cancer (IARC) working group assessment of the rubber 
manufacturing industry in 1982 concluded that workers with documented exposure to 2-naphthylamine 
were at an increased risk of cancer of the urinary bladder 1. In its most recent evaluation, in 2012, the 
IARC working group identified an increased risk for leukaemia, possibly due to exposure to solvents, 
such as benzene, as well as sufficient evidence of increased risks of non-Hodgkin’s lymphoma (NHL), 
multiple myeloma, and lung and stomach cancers. The evidence for laryngeal cancer and prostate cancer 
was deemed inconsistent, and that for oesophageal cancer was considered weak. For other cancer sites, 
the evidence was regarded as insufficient 2. In addition to these increased cancer risks, several other 
studies of rubber industry workers suggest potentially higher levels of certain respiratory 3,4 and 
circulatory 4,5 diseases.  
The previous analysis of the current study cohort examined the mortality of 40,867 men in the British 
industry over a 10-year follow-up period. The main finding was that an excess risk of bladder cancer 
was shown in men with exposure to antioxidants (containing trace amounts of 1- and 2-naphthylamine) 
that may have occurred before the compounds were withdrawn in 1949, with no such risk in men who 
had joined after 1949 or who had worked in factories where those antioxidants had never been used. 
Other significant findings included an overall excess of lung cancer in the industry, associated with 
rubber fume, and an excess of stomach cancer, probably associated with exposure to rubber dust in the 
tyre manufacturing sector 6. 
The current study extends the previous 10-year follow-up to 49 years and compares the mortality 
experience of this cohort of rubber industry workers with the general population of England and Wales, 
examining Standardised Mortality Ratios (SMR) by decade of employment start, industrial sector, and 
department. A priori important disease groups were those cancer sites examined previously by IARC, 
namely leukaemia, NHL, multiple myeloma, and cancers of the urinary bladder, lung, stomach, prostate, 
oesophagus, and larynx, as well as non-malignant respiratory diseases (NMRDs) and circulatory 
diseases (CDs).  
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Methods 
Assembly of Study Cohort 
The original census to recruit workers into the cohort was initiated in 1967 by a predecessor to the UK 
Health and Safety Executive (HSE). In the previous analysis6, 40,867 workers were included once 
women, men younger than 35 years of age, or those employed in the rubber industry for less than one 
year, together with those who could not be traced, were excluded. As well as the start year for working 
in the industry, the occupational data ascertained during the original survey included job position, 
factory of employment, industry sector (e.g., tyres, cables, hoses), and department, all at the time of 
study recruitment only, with the information for each participant recorded on individual study cards. In 
addition, exposure to antioxidants was recorded based on the findings from a 1965 survey by the HM 
Factory Inspectorate. The categories were as follows: group A - started work before 1 January 1950 in 
a factory which used the suspect antioxidants; group B started work on or after 1 January 1950 in a 
factory which had used the suspect antioxidants; and group C – worked in factories which had never 
used the suspect antioxidants 6-9. For this analysis, the cohort had to be retraced from original study 
cards, which could only be located for 37,626 (92%) workers. Individuals were censored at the time of 
cancellation of registration with a GP or emigration (n = 136). Although the tracing exercise extended 
beyond 2015, the number of deaths reported in 2016 was incomplete compared to 2014 and 2015 (125 
deaths vs 306 and 297, respectively). Thus, follow-up was extended until 31 December, 2015, a total 
of 49 years. After exclusion of unmatched or non-uniquely matched records, those not adhering to the 
initial study inclusion criteria (e.g., <35 years of age at study start), and checks for internal consistency 
(e.g., year of first employment ≥ birth year+14), the final cohort for available analysis consisted of 
36,442 workers (89.2% of the original cohort). A total of 1939 deceased workers included a death date, 
but no cause of death; these deaths were included only in the all-cause mortality analysis. Fifteen job 
groups, based on the British Rubber Manufacturing Association classification, were originally included 
in the survey, and were allocated into four departments for analysis purposes (see Table 1).  
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The study obtained clearances from an NHS ethics committee (Ref: 13/NW/0543), the Health Research 
Authority’s Confidentiality Advisory Group (Ref: CAG 5-08(d)/2013), the Office for National 
Statistics, and NHS Digital’s Data Access Advisory Group (now Independent Group Advising on the 
Release of Data, Ref: NIC-323309-L2G9T). 
Data Analysis 
Population estimates and number of deaths by cause for males in England and Wales from 1967-2015 
were obtained from the Office for National Statistics (ONS). Annual 5-year male reference rates were 
calculated for causes of death for each year in the follow-up period (1967-2015) (see Supplementary 
Table 1 for a list of ICD disease codes).  Person-years, SMRs, 95% Confidence Intervals (CIs), and 
Breslow & Day tests for trends and homogeneity 8,9 were carried out using Stata’s ‘strate’ and ‘smrby’ 
commands 10. SMRs were reported where there are at least five observed deaths. 
For a priori important causes of death (based on the IARC monograph conclusions and some early 
studies for non-malignant diseases) SMRs were also compared by decade of start in the industry, tyre 
and non-tyre (e.g., moulding, footwear) industries, and department. Sensitivity analyses were 
undertaken to examine any differences in SMR results for rubber industry-related health outcomes if 
individuals aged 90 years or older were censored, as well as for all individual job groups 
(Supplementary Table 3). 
 
Results 
Table 1 presents descriptive characteristics of the study cohort. The workforce was distributed fairly 
evenly across the age groups 35-44, 45-54, and 55-64 at start of follow-up, with 2.1% of the cohort aged 
65 or over. Almost 5% of the cohort began work in the industry before 1930, nearly 10% during the 
1930s, and just over 20% during the 1940s. Slightly over 40% of workers were employed in tyre 
manufacturing. Around 10% worked with crude materials, and around 20% were involved in pre-
processing operations, with over 10% in curing/vulcanising and the remainder in finishing. Over 90% 
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of the cohort were deceased at the end of follow-up with just under 95% of the deaths including a coded 
cause of death. 
For the a priori selected causes of death, statistically significantly elevated SMRs were obtained for all 
causes, all MNs, and for cancers of the stomach, lung, bladder, and NMRDs and CDs (Table 2). SMRs 
were not different to those expected for multiple myeloma, leukaemia, NHL, and cancers of the larynx, 
oesophagus, and prostate. Undertaking the SMR analysis with the exclusion of those aged 90 years or 
older had a negligible impact on study findings (data not shown). 
Assessing SMRs across decade of employment start (Table 3) showed statistically significant increasing 
trends for all causes (p < 0.001), all neoplasms (p = 0.017), all causes excluding neoplasms (p < 0.001), 
lung cancer (p < 0.001), CDs (p = 0.041), and NMRDs (p < 0.001). The exception to the direction of 
these trends was bladder cancer, which exhibited a strong decreasing SMR trend across decade (p = 
0.015) and only demonstrated a significantly increased SMR for those starting employment before 1930 
(n = 36) (1.89 [95% CI 1.37 to 2.63]). Bladder cancer was the only a priori selected endpoint that was 
increased in workers starting before 1949 (n = 170) (1.33 [95% CI 1.15 to 1.55]), but not during or after 
1949 (n=247) (1.06 [95% CI 0.94 to 1.20]) (See Supplementary Table 2). SMRs were significantly 
increased for bladder cancer only amongst those who worked in factories that used 1- and 2-
naphthylamine prior to 1949 (n = 156) (1.32 [95% CI 1.13 to 1.54]). No increase was evident for those 
who started work in such factories after 1949 (n = 165) (1.07 [95% CI 0.92 to 1.25]), nor in facilities in 
which those substances had never been used (n = 96) (1.10 [95% CI 0.90 to 1.34]). 
Examination of SMRs in the tyre and non-tyre sectors of the rubber industry (Table 4) indicated 
significant differences for stomach cancer, which was higher in the tyre (n = 343) (1.38 [95% CI 1.23 
to 1.53]) than non-tyre industries (n = 425) (1.19 [95% CI 1.08 to 1.31]) (p = 0.042), but still 
significantly elevated in both sectors. The risk of NMRDs, whilst also significantly raised in both 
sectors, was higher in the non-tyre (n = 2,856) (1.17 [95% CI 1.13 to 1.21]) compared to the tyre sector 
(n = 1,874) (1.09 [95% CI 1.04 to 1.14]) (p = 0.019). The NHL SMR was found to be significantly 
lower in the tyre sector of the rubber industry (n = 47) (0.69 [95% CI 0.52 to 0.92]), but was not different 
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from unity in the non-tyre sectors (n = 96) (0.99 [95% CI 0.81 to 1.21]) (p = 0.037). No differential 
excess risks were observed in the tyre or non-tyre sectors for cancers of the oesophagus, larynx, or 
prostate, or for leukaemia, multiple myeloma, or CDs. 
Conducting analyses by departments (Table 5) showed that SMRs tended to be highest in “Crude 
materials” and lowest in “Finishing” across many of the a priori important disease groups. Formally 
assessing SMRs gave statistically significant heterogeneity for all causes (p < 0.001), all malignant 
neoplasms (p < 0.001), all causes excluding neoplasms (p < 0.001), lung cancer (p < 0.001), CDs (p = 
0.003), and NMRDs (p < 0.001). The pattern was noticeably different for bladder cancer, with the 
highest SMR in “Pre-processing” (n = 107) (1.41 [95% CI 1.16 to 1.70]; p = 0.131). For the other a 
priori important disease groups, risks were homogeneous between departments.  
The results by individual job groups mainly presented the same patterns as the analysis by department. 
However, there were additional instances of significantly increased SMRs that had not been evident in 
the analysis by department: leukaemia in commercial staff and oesophageal cancer in both extruding 
and inspection workers (see Supplementary Table 3). 
 
Discussion 
This study sought evidence in relation to the risks of working in the British rubber and cable 
manufacturing industry using a large cohort that has not been studied since 1980 6, by extending the 
follow-up to 49 years, and which resulted in 93% mortality. The overall SMR for bladder cancer of 
1.16 is lower than that for lung cancer, and is also potentially influenced by tobacco smoking. In 
contrast to lung cancer, the SMR by decade first employed has decreased substantially, from just 
under 2.0 for those first employed before 1930 to not significantly raised above one for those first 
employed in any subsequent decade. Bladder cancer SMRs were significantly elevated for the tyre 
and non-tyre sectors, but only elevated for pre-processing operations, and, in particular, those working 
in extruding and component buildings. The data support the notion that working in the industry 
conferred an increased risk of bladder cancer, but only for those exposed to antioxidants containing 1- 
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and 2-naphthylamine (and maybe others), which were withdrawn from use in 1949. Research from 
other countries has also identified increased bladder cancer risks only for pre-1950s employment in 
the industry 4.  
This study provided some evidence of raised risks of ischaemic heart disease and bronchitis, risks of 
which are both strongly influenced by tobacco smoking. The finding for ischaemic heart disease 
seems to be uniformly elevated across all decades workers first started employment in the industry, 
whereas for bronchitis the risk increased with decade starting employment. The excesses of both of 
these endpoints were found in the non-tyre industries and in the four main job groups for ischaemic 
heart disease, but, for bronchitis, only in the crude materials and pre-processing groups. An excess of 
mortality from chronic, but not acute, ischaemic heart disease was identified in an earlier study 11, 
whilst a meta-analysis (excluding the earlier study) identified lowered risks in rubber industry workers 
12; meta-SMRs for bronchitis were as expected in that study. Our findings of increased mortality in 
these non-cancer endpoints warrant further investigation to see if they are related to working in the 
industry.  
 
Our study found statistically significantly increased SMRs for cancers of the stomach, lung, and 
bladder, but not for multiple myeloma, leukaemia, NHL, or for cancers of the oesophagus, larynx, or 
prostate. Thus, our findings are largely consistent with those of IARC, except that we found no 
increase in risk for leukaemia, NHL, or multiple myeloma.  
The overall SMR for lung cancer of 1.25 is at a level where the excess risk could be due to 
confounding by tobacco smoking; however, we did not have data on the smoking history of cohort 
members. A study examining the role of tobacco smoking and lung cancer in the rubber industry 
found excess rate ratios in the curing department after adjusting for smoking, and suggested that the 
excess could be partially due to exposure to n-Nitrosamines in the process 13. In the present study 
there was a highly statistically significant trend for increasing lung cancer SMRs from those first 
employed in the industry before 1930 through to those first employed in the 1960s, which mirrors the 
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general rise of per capita tobacco product use in the UK 14,15. This SMR is significantly raised in the 
tyre and non-tyre sectors and, although raised in all job groups, is lower in finishing than the others. 
Such analyses need to be treated cautiously since surrogate indicators of exposure in occupational 
cohort studies can lead to an over-estimation of risks, especially for low-risk jobs and work areas 16. 
Studies published since the latest IARC review 2 have also found increased lung cancer risks 17,18. 
The overall SMR for stomach cancer was similar to that for lung cancer; tobacco smoking also 
influences the risk of this tumour. No trend in SMRs by decade of first employment was seen for 
stomach cancer and, as in the earlier follow-up6, the excess was higher in the tyre sector, but also 
significantly raised in the non-tyre sectors. Stomach cancer risk was elevated for workers in the crude 
materials and pre-processing departments and particularly for compounding, latex mixing, extruding, 
inspection, site working, and engineering jobs. Recent studies have not found an increased stomach 
cancer risk in the rubber industry.17-22  
None of the overall SMRs for multiple myeloma, leukaemia, or NHL was in excess. Another study 
based on the UK rubber industry identified a significantly increased risk of mortality from multiple 
myeloma, but this was based on only seven cases 23. In the current study, there was a significant 
excess of leukaemia among commercial staff, but this could be due to chance rather than employment 
in the rubber industry given the low number of cases involved. Since the IARC review, only one study 
has found a relationship between time since first exposure and leukaemia risk, but there was no 
overall excess 22. Although a meta-analysis found consistent evidence of raised risks for laryngeal 
cancer, with some positive findings for oesophageal cancer and prostate cancer from working in the 
rubber manufacturing industry 24, such risks were not identified in the present study. The absence of 
laryngeal and oesophageal cancers may suggest that smoking levels may not have been higher in the 
rubber industry compared to the general population, since these cancers are also linked to tobacco 
smoking 25.  
To the best of our knowledge, this study constitutes the longest and most complete follow-up of the 
mortality of men employed in the rubber manufacturing industry in the UK. We carried out sensitivity 
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analyses relating to deaths in older ages and this had no impact on any of our analyses and, therefore, 
our conclusions. These strengths notwithstanding, the study had a number of limitations that warrant 
discussion. Firstly, this was a prospective cohort based on a census of the industry carried out in 1967. 
As such, there is evidence, including increasing trends with later decade of employment start, that 
suggests there is a healthy worker survivor effect 26-29 operating in this study; workers in the industry 
would have had to have survived and still be working in the industry by 1967 to have been included in 
the cohort. At the same time, it should also be noted that there is a distinct absence of a healthy 
worker effect due to the long follow-up of the cohort 29,30 as exemplified by significantly elevated 
SMRs from NMRDs and CDs, and so it is unlikely that the SMRs in this study will be biased towards 
the null by this. Secondly, we did not have complete work histories for the cohort, only job held at the 
time of recruitment into the study. This limited our ability to take account of different jobs over time 
and to explore carcinogenic and other mortality risks by job title in more detail. Thirdly, we had no 
information on smoking or any other important risk factors, such as work in other industries, exposure 
to asbestos, or diet. This omission could have resulted in a bias in those SMRs potentially affected by 
these risk factors. Our findings will also be subject to multiple significance testing 31. In addition, this 
analysis only contained mortality data, and a future analysis of cancer incidence data is warranted for 
less fatal cancers, such as leukaemia. 
An internet search of a sample of factories suggested that most incorporated in the original study have 
since closed, and remaining factories in the UK will have experienced improved hygiene standards 
and/or employed enhanced automation, both contributing to observed reductions in overall exposures 
32. Nevertheless, with global production of natural and synthetic rubber in 2016 in excess of 25 million 
tonnes, many workers around the world remain exposed to process generated emissions in rubber 
manufacturing 33. Our results indicate potentially higher risks in the earlier stages of manufacturing, so 
continued research is needed to identify causative agents, especially in this stage of the process. Efforts 
should continue be made to reduce employee exposures to dust and fumes throughout the production 
process. 
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This study provides evidence that bladder cancer risk has declined in the industry, that there are 
increased risks for mortality from ischaemic heart disease and bronchitis and supports IARC’s 
conclusions in relation to risks in the rubber industry for cancers of the bladder, lung, and stomach. 
IARC’s conclusions for leukaemia, NHL, or multiple myeloma were not supported. Extension of this 
study to include cancer incidence and its inclusion in an international pooled study would further help 
clarify carcinogenicity from working in the industry. 
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Table 1. Characteristics of study population of rubber workers (n = 36,442). 
Characteristic n (%) Person-years 
Age in 1967  (at study start) (years)    
35-44 11,595 (31.8) 387,592  
45-54 13,220 (36.3) 315,067  
55-64 10,852 (29.8) 170,706  
65+ 775 (2.1) 8,822  
   
Decade of employment start   
<1930  1801 (4.9)  29,533  
1930-1939  3570 (9.8)  76,074  
1940-1949  7798 (21.4)  180,841  
1950-1959  12,439 (31.1)  314,239  
1960-1966  10,834 (29.7)  281,500  
   
Industry sector   
Tyre  14,906 (40.9)  362,093 
Non-tyre  21,536 (59.1)  520,094 
   
Departments 
    Job  groups 
Crude Materials   
    Storeman  178 (0.5)  3,767 
    Compounding 
Pre-processing 
 3574 (9.8)  
 
83,431 
 
    Latex Mixing  424 (1.2)  9,586 
    Extruding & calendaring  3461 (9.5)  82,664 
    Component building 
Curing/Vulcanising 
 4037 (11.1)  
 
101,068 
 
    Moulding   4710 (12.9)  118,909 
Finishing 
    Inspection  1954 (5.4)  46,239 
    Finished goods  2375 (6.5)  52,914 
    Site workers  2056 (5.6)  42,105 
    Engineering  6137 (16.8)  144,483 
    Canteens  30 (0.1)  606 
    Factory operations  5728 (15.7)  146,273 
    Commercial staff  485 (1.3)  13,381 
    Engineering staff  378 (1.0)  10,490 
    Technical staff  915 (2.5)  26,272 
   
Vital Status   
Alive1 2125 (5.8%) 99,110 
Dead 34,181 (93.8%) 781,001 
Dead, no cause of death 1939 (5.3%) 38,976 
Embarked/ Registration cancelled 136 (0.4%) 2,075 
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Total2 36,442 (100)  882,187 
1 Includes 125 deaths where date of death > 31 December, 2015 
2 Excludes 4425 untraced individuals from the original study (n=40,867). 
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Table 2 – Overall Standardised Mortality Ratios (SMRs) using England & Wales reference rates 
during 1967-2015. 
 
Cause of death n SMR 95% CI 
Including missing cause of death 34,181 1.11 1.10 to 1.12 
Excluding missing cause of death 32,242 1.08 1.07 to 1.10 
All neoplasms  9,227 1.13 1.11 to 1.16 
All causes excluding neoplasms  23,025 1.06 1.05 to 1.08 
All malignant neoplasms (MNs)  9,101 1.14 1.12 to 1.16 
MN Buccal cavity and pharynx  89 0.93 0.75 to 1.14 
MN Nasopharynx  6 0.80 0.36 to 1.78 
MN Larynx  62 0.94 0.74 to 1.21 
MN Oesophagus  333 1.05 0.95 to 1.17 
MN Stomach  768 1.26 1.18 to 1.36 
MN Colon  569 1.08 1.00 to 1.17 
MN Rectum and rectosigmoid junction 407 1.22 1.10 to 1.34 
MN Liver 122 0.95 0.80 to 1.14 
MN Pancreas  328 1.01 0.91 to 1.12 
MN Nose  7 0.72 0.34 to 1.51 
MN Trachea, bronchus and lung  3,380 1.25 1.21 to 1.29 
MN Prostate  885 1.01 0.94 to 1.07 
MN Bladder  417 1.16 1.05 to 1.28 
MN Kidney and other urinary organs  167 1.09 0.94 to 1.27 
MN Brain  106 0.88 0.73 to 1.07 
MN Lymphatic and haematopoietic tissue:  462 0.94 0.86 to 1.03 
Hodgkin’s disease  19 0.84 0.54 to 1.32 
Multiple Myeloma  105 1.00 0.82 to 1.21 
Leukaemia  195 1.04 0.90 to 1.19 
Non-Hodgkin’s lymphoma (NHL)  143 0.87 0.74 to 1.02 
Endocrine nutritional and metabolic diseases  308 0.90 0.80 to 1.01 
Diabetes mellitus  263 0.90 0.80 to 1.01 
Diseases of circulatory system (CDs) 14,627 1.07 1.05 to 1.09 
Ischaemic heart disease  9,349 1.08 1.06 to 1.10 
Cerebrovascular disease  2,795 1.04 1.00 to 1.08 
Diseases of respiratory system (NMRDs) 4,730 1.14 1.10 to 1.17 
Bronchitis  842 1.09 1.02 to 1.17 
Emphysema  163 1.19 1.02 to 1.38 
Asthma  63 1.15 0.90 to 1.47 
Diseases of the digestive system  828 1.00 0.93 to 1.07 
Diseases of oral cavity, salivary grands and jaws  3 - - 
Diseases of oesophagus, stomach and duodenum  258 1.01 0.89 to 1.14 
Peptic ulcer  220 1.02 0.89 to 1.16 
Disease of the liver  106 0.79 0.65 to 0.95 
Cirrhosis of liver  83 0.76 0.61 to 0.94 
Diseases of genitourinary system  435 1.03 0.93 to 1.13 
Nephritis and nephrosis  207 1.01 0.88 to 1.16 
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Accidents  440 1.00 0.92 to 1.10 
Suicides  82 0.63 0.50 to 0.78 
Notes:  
A priori important diseases in bold. 
See Supplementary Table 1 for ICD codes used.    
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Table 3. Standardised Mortality Ratios (SMRs) by decade of employment start in the rubber industry for selected causes of death during 1967-2015 (using 
England & Wales reference rates). 
 
  Decade of Employment Start   
  <1930 1930-39 1940-49 1950-59 1960-66   
Cause of Death n SMR  95% CI n SMR  95% CI n SMR  95% CI n SMR  95% CI n SMR  95% CI 
p-value 
for Trend 
All causes                                 
   Incl missing cause 
of death 
1,787 1.04 0.99 to 1.09 3,505 1.06 1.02 to 1.09 7,410 1.08 1.05 to 1.10 11,515 1.11 
1.09 to 
1.13 
9,96
4 
1.17 
1.14 to 
1.19 
<0.001 
   Excl missing cause 
of death 
1,671 1.04 0.99 to 1.09 3,288 1.04 1.00 to 1.07 6,985 1.06 1.03 to 1.08 10,876 1.08 
1.06 to 
1.10 
9,42
2 
1.13 
1.11 to 
1.16 
<0.001 
All neoplasms 420 1.08 0.98 to 1.18 920 1.11 1.04 to 1.18 1,983 1.12 1.07 to 1.16 3,096 1.11 
1.07 to 
1.15 
2,80
8 
1.20 
1.15 to 
1.24 
0.017 
All cause excl 
neoplasms 
1,251 1.03 0.97 to 1.09 2,368 1.01 0.97 to 1.05 5,002 1.03 1.00 to 1.06 7,785 1.07 
1.04 to 
1.09 
6,61
9 
1.11 
1.08 to 
1.13 
<0.001 
All malignant 
neoplasms 
415 1.08 0.97 to 1.18 909 1.12 1.04 to 1.19 1,956 1.12 1.07 to 1.17 3,048 1.11 
1.07 to 
1.15 
2,77
3 
1.21 
1.16 to 
1.25 
0.012 
MN Larynx 4 - - 6 0.90 0.33 to 1.96 9 0.63 0.29 to 1.19 25 1.11 
0.72 to 
1.64 
18 0.95 
0.56 to 
1.50 
0.822 
MN Oesophagus 14 1.18 0.65 to 1.99 27 0.91 0.60 to 1.33 57 0.85 0.64 to 1.10 118 1.06 
0.87 to 
1.27 
117 1.22 
1.01 to 
1.46 
0.130 
MN Stomach cancer 41 1.11 0.80 to 1.51 76 1.14 0.90 to 1.43 176 1.29 1.11 to 1.50 262 1.30 
1.14 to 
1.46 
213 1.29 
1.12 to 
1.47 
0.365 
MN Trachea, 
bronchus and lung 
143 0.98 0.83 to 1.16 331 1.16 1.03 to 1.29 739 1.24 1.15 to 1.33 1,080 1.18 
1.11 to 
1.25 
1,08
7 
1.43 
1.34 to 
1.51 
<0.001 
MN Prostate 33 0.80 0.57 to 1.13 114 1.24 1.03 to 1.48 208 1.07 0.93 to 1.22 278 0.92 
0.82 to 
1.03 
252 1.01 
0.89 to 
1.14 
0.446 
MN Bladder 36 1.89 1.37 to 2.63 47 1.24 0.93 to 1.65 93 1.16 0.95 to 1.43 139 1.14 
0.96 to 
1.34 
102 1.01 
0.83 to 
1.23 
0.015 
Multiple Myeloma 5 1.11 0.46 to 2.66 12 1.13 0.64 to 2.00 25 1.10 0.74 to 1.62 29 0.79 
0.55 to 
1.14 
34 1.10 
0.78 to 
1.54 
0.779 
Leukaemia 12 1.44 0.82 to 2.54 24 1.31 0.88 to 1.95 34 0.84 0.60 to 1.17 66 1.01 
0.79 to 
1.28 
59 1.06 
0.82 to 
1.37 
0.542 
Non-Hodgkin's 
Lymphoma 
3 - - 9 0.59 0.31 to 1.14 35 1.00 0.72 to 1.40 46 0.79 
0.59 to 
1.05 
50 0.99 
0.75 to 
1.30 
0.272 
Circulatory Diseases 842 1.08 1.01 to 1.15 1,552 1.04 0.99 to 1.09 3,170 1.03 1.00 to 1.07 4,949 1.08 
1.05 to 
1.09 
4,11
4 
1.09 
1.06 to 
1.13 
0.091 
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Ischaemic Heart 
Disease 
514 1.08 0.99 to 1.18 992 1.06 0.99 to 1.13 2054 1.07 1.02 to 1.11 3159 1.09 
1.05 to 
1.13 
263
0 
1.09 
1.05 to 
1.14 
0.423 
Respiratory 
Diseases 
226 0.88 0.78 to 1.01 443 0.95 0.87 to 1.05 1,051 1.11 1.05 to 1.18 1,595 1.15 
1.10 to 
1.21 
1,41
5 
1.27 
1.21 to 
1.34 
<0.001 
Bronchitis 63 0.85 0.66 to 1.08 86 0.92 0.74 to 1.13 189 1.03 0.90 to 1.19 264 1.11 
0.99 to 
1.26 
240 1.32 
1.17 to 
1.50 
<0.001 
Emphysema 10 1.28 0.69 to 2.38 12 0.79 0.45 to 1.39 34 1.10 0.79 to 1.54 53 1.15 
0.88 to 
1.51 
54 1.44 
1.10 to 
1.87 
0.186 
                 
 
 
23 
 
Table 4. Standardised Mortality Ratios (SMRs) for workers in tyre and non-tyre sectors in the rubber industry for selected causes of death during 1967-2015 
(using England & Wales reference rates). 
 
 Industry Group   
 Tyre Non-Tyre   
Cause of death  n SMR  95% CI n SMR  95% CI 
Test for homogeneity 
(Χ2) 
p-value 
All causes         
   Incl missing cause of death 13,929 1.10 1.08 to 1.12 20,252 1.11 1.10 to 1.13 1.64 0.201 
   Excl missing cause of death 13,223 1.08 1.06 to 1.09 19,019 1.09 1.07 to 1.10 0.87 0.352 
All neoplasms 3,837 1.14 1.11 to 1.18 5,390 1.13 1.10 to 1.16 0.36 0.549 
All cause excl neoplasms 9,390 1.05 1.03 to 1.07 13,635 1.07 1.05 to 1.09 2.23 0.136 
All malignant neoplasms 3,789 1.15 1.11 to 1.19 5,312 1.13 1.10 to 1.16 0.25 0.614 
MN Larynx 26 0.96 0.63 to 1.41 36 0.93 0.65 to 1.29 0.02 0.899 
MN Oesophagus 150 1.15 0.97 to 1.35 183 0.99 0.85 to 1.14 1.86 0.172 
MN Stomach cancer 343 1.38 1.23 to 1.53 425 1.19 1.08 to 1.31 4.13 0.042 
MN Trachea, bronchus and lung 1,393 1.25 1.19 to 1.32 1,987 1.25 1.19 to 1.30 0.01 0.94 
MN Prostate 383 1.05 0.95 to 1.16 502 0.98 0.89 to 1.07 1.09 0.297 
MN Bladder 173 1.16 1.00 to 1.35 244 1.16 1.02 to 1.31 0.01 0.94 
Multiple Myeloma 49 1.13 0.85 to 1.49 56 0.90 0.70 to 1.18 1.25 0.264 
Leukaemia 78 1.00 0.80 to 1.25 117 1.06 0.88 to 1.27 0.15 0.699 
Non-Hodgkin's Lymphoma 47 0.69 0.52 to 0.92 96 0.99 0.81 to 1.22 4.33 0.037 
Circulatory Diseases 5,968 1.06 1.03 to 1.09 8,659 1.08 1.05 to 1.10 0.82 0.365 
Ischaemic Heart Disease 3,811 1.07 1.04 to 1.11 5,538 1.09 1.06 to 1.12 0.57 0.449 
Respiratory Diseases 1,874 1.09 1.04 to 1.14 2,856 1.17 1.13 to 1.21 5.49 0.019 
Bronchitis 322 1.03 0.93 to 1.15 520 1.13 1.04 to 1.24 1.71 0.192 
Emphysema 54 0.96 0.73 to 1.25 109 1.35 1.12 to 1.63 4.34 0.037 
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Table 5. Standardised Mortality Ratios (SMRs) for workers in different departments in the rubber industry for selected causes of death during 1967-2015 
(using England & Wales reference rates). 
 Job Groups   
 Crude Materials Pre-processing Curing/vulcanising Finishing   
Cause of death  n SMR  95% CI n SMR  95% CI n SMR  95% CI n SMR  95% CI 
Test for 
homogeneity 
(Χ2) 
p-value 
All causes               
   Incl missing cause of death 3,578 1.19 1.15 to 1.23 7,441 1.14 1.12 to 1.17 4,434 1.14 1.10 to 1.17 18,728 1.07 1.06 to 1.09 49.8 <0.001 
   Excl missing cause of death 3,359 1.17 1.13 to 1.21 7,037 1.12 1.09 to 1.15 4,193 1.11 1.08 to 1.15 17,653 1.05 1.03 to 1.06 49.72 <0.001 
All neoplasms 972 1.24 1.16 to 1.32 2,064 1.19 1.14 to 1.24 1,244 1.19 1.12 to 1.25 4,947 1.08 1.05 to 1.11 25.11 <0.001 
All cause excl neoplasms 2,388 1.14 1.10 to 1.19 4,976 1.09 1.06 to 1.12 2,949 1.08 1.06 to 1.12 12,712 1.03 1.02 to 1.05 27.07 <0.001 
All malignant neoplasms 956 1.24 1.16 to 1.32 2,037 1.20 1.14 to 1.25 1,228 1.20 1.13 to 1.26 4,880 1.09 1.06 to 1.12 24.02 <0.001 
MN Larynx 9 1.40 0.64 to 2.66 14 1.00 0.54 to 1.67 4 - - 35 0.95 0.66 to 1.32 3.48 0.323 
MN Oesophagus 28 0.94 0.62 to 1.35 83 1.22 0.97 to 1.51 48 1.15 0.85 to 1.53 174 0.99 0.84 to 1.14 3.36 0.339 
MN Stomach cancer 86 1.42 1.14 to 1.75 180 1.40 1.20 to 1.62 89 1.16 0.93 to 1.43 413 1.21 1.10 to 1.33 4.38 0.223 
MN Trachea, bronchus and lung 393 1.47 1.32 to 1.62 775 1.34 1.25 to 1.44 467 1.35 1.23 to 1.47 1,745 1.15 1.10 to 1.21 27.52 <0.001 
MN Prostate 76 0.93 0.75 to 1.17 165 0.89 0.76 to 1.04 123 1.10 0.92 to 1.32 521 1.04 0.95 to 1.13 4.39 0.222 
MN Bladder 39 1.13 0.83 to 1.55 107 1.41 1.16 to 1.70 54 1.18 0.91 to 1.55 217 1.06 0.93 to 1.22 5.64 0.131 
Multiple Myeloma 9 0.89 0.46 to 1.71 22 0.97 0.64 to 1.48 15 1.09 0.66 to 1.81 59 1.00 0.77 to 1.29 0.25 0.969 
Leukaemia 23 1.29 0.86 to 1.94 41 1.02 0.75 to 1.38 28 1.15 0.79 to 1.67 103 0.97 0.80 to 1.18 1.8 0.614 
Non-Hodgkin's Lymphoma 12 0.77 0.44 to 1.36 35 0.98 0.71 to 1.37 17 0.78 0.49 to 1.26 79 0.86 0.69 to 1.07 0.91 0.824 
Circulatory Diseases 1,512 1.13 1.08 to 1.19 3,206 1.11 1.07 to 1.15 1,838 1.06 1.02 to 1.11 8,071 1.04 1.02 to 1.07 14.04 0.003 
Ischaemic Heart Disease 961 1.13 1.06 to 1.20 1999 1.09 1.04 to 1.14 1166 1.06 1.00 to 1.12 5223 1.07 1.05 to 1.10 2.65 0.448 
Respiratory Diseases 512 1.29 1.18 to 1.41 1,024 1.18 1.11 to 1.26 647 1.26 1.16 to 1.36 2,547 1.07 1.03 to 1.11 26.55 <0.001 
Bronchitis 101 1.25 1.03 to 1.52 185 1.17 1.01 to 1.35 102 1.12 0.93 to 1.36 454 1.03 0.94 to 1.13 4.22 0.239 
Emphysema 12 0.89 0.51 to 1.57 27 0.93 0.64 to 1.35 20 1.15 0.74 to 1.78 104 1.34 1.11 to 1.63 4.20 0.241 
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